premargin

Element List	Explanation
Introduction	Arabian International Healthcare Holding Company (“Tibbiyah”) announces that it has entered into a conditional share purchase agreement on 31 December 2025 to sell its 51% equity interest in Innovative Healthcare Holdings Ltd. for a total consideration of SAR 52 million, implying an equity value of SAR 101.96 million for 100% of the company. The transaction will result in the dissolution of the partnership between Tibbiyah and Dr. Aayed Rubaian Saleh Al-Qahtani in the obesity and aesthetic sector.
Transaction Details	To sell 51% of Innovative Healthcare Holding Company.
Transaction Amount	SAR 52,000,000
Transaction Conditions	The agreement is subject to several conditions’ precedent prior to the completion of the shares transfer, which is the subject matter of the transaction, including —without limitation— obtaining all required regulatory approvals within the United Araba Emirates.
Parties of the Transaction	Buyer: LE MONDE HOLDING LTD, incorporated under the laws of the Abu Dhabi Global Market, with registered number 000007042 and registered office is at Al Sila Tower, Abu Dhabi Global Market Square, Al Maryah Island, United Arab Emirates. Seller: Arabian International Healthcare Holding Company with registered number 1010380429 and office is at Business Gate, Eastern Ring Road, P.O. Box 16460, Riyadh 11464, Kingdom of Saudi Arabia.
Transaction Financing Method	Not applicable
Date of Entering Into The Transaction	2025-12-31 Corresponding to 1447-07-11
Description of Activity of The Asset Subject of The Transaction	Clinics and day surgery center specialized in obesity and aesthetic.
Asset Book Value	The book value of the asset is estimated at SAR 50.0 million, subject to final year-end closing adjustments.
Financial Statements for the Last Three Years of the Asset forming the Subject Matter of the Transaction	With regard to Innovative Healthcare Holding Ltd. Company: Revenue: 2025 (Estimated): SAR 69.1 million 2024: SAR 75.1 million 2023: SAR 96.7 million Net Income / (Loss): 2025 (Estimated): SAR (6.5) million 2024: SAR (5.6) million 2023: SAR 11.4 million
Transaction reasons	The Company resolved to divest its investment after assessing material changes in the obesity treatment market, driven by the rapid adoption of GLP-1 anti-obesity medications, which led to a structural decline in demand for surgical obesity procedures. This development adversely impacted the addressable market, scalability, and expected profitability of the investment. Accordingly, the Board determined that the investment no longer aligned with the Company’s strategic objectives, and approved the divestment in order to optimize capital allocation and redeploy proceeds into strategically aligned opportunities.
Expected Impact of the Transaction on the Company and Its Operations	• Following the execution of the binding agreement on 31 December 2025, Innovative HealthCare will be deconsolidated from Tibbiyah’s consolidated financial statements effective the same date. • The disposal consideration exceeds the net book value of the investment by a non-material margin; accordingly, the transaction is not expected to result in a material impact on the income statement for the financial year 2025.
Details of Using The Proceeds of the Asset Sale	The proceeds from the transaction will be utilized in accordance with the agreed payment terms to strengthen the Company’s financial fundamentals, settle Company’s obligations and support its strategic initiatives, with any related disclosures to be made in accordance with applicable regulatory requirements.
Related Parties	None

Arabian International Healthcare Holding Co. Announces the Selling of Company in the amount of SAR 52,000,000